The new episode covers how food choices shape memory and cravings, with chapters on natural GLP-1, GLP-1 drugs, microdosing and hunger.
Recap by typeshit. Post by Andrew D. Huberman, Ph.D. on X.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Piotr Alvarez and Nitish Sharma cover flow rate, temperature, dwell volume and TFA levels, and why robustness testing decides whether a method transfers cleanly.
Investors wanted a near-term plan but got 2030 targets instead, while CagriSema missed against Zepbound and Morgan Stanley downgraded the stock over the semaglutide patent cliff.
Loading…